Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock

Lancet

Volumn 351, Issue 9107, 1998, Pages 929-933

  Abraham, Edward ^a   Anzueto, Antonio ^b   Gutierrez, Guillermo ^c   Tessler, Sidney ^d   San Pedro, Gerry ^e   Wunderink, Richard ^f   Dal Nogare, Anthony ^g   Nasraway, Stanley ^h   Berman, Steve ⁱ   Cooney, Robert ^j   Levy, Howard ^k   Baughman, Robert ^l   Rumbak, Mark ^m   Light, R Bruce ⁿ   Poole, Lona ^o   Allred, Randy ^o   Constant, John ^o   Pennington, James ^o   Porter, Steven ^o  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c MEMORIAL HERMANN HOSPITAL   (United States)

^d MAIMONIDES MEDICAL CENTER   (United States)

^e LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h TUFTS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF HAWAII   (United States)

^j PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^k UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^l UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^m UNIVERSITY OF SOUTH FLORIDA   (United States)

ⁿ UNIVERSITY OF MANITOBA   (Canada)

^o BAYER CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADVERSE DRUG REACTION; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SURVIVAL;

EID: 0032495658     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60602-2     Document Type: Article

References (25)

1. 1 Wenzel RP. Anti-endotoxin monoclonal antibodies: a second look. N Engl J Med 1992; 326: 1151-53.
2. 2 Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Ann Intern Med 1990; 113: 227-42.
3. 3 Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-58.
4. 4 The HA-1A Sepsis Study Group. Treatment of gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind placebo-controlled trial. N Engl J Med 1991; 324: 429-36.
5. 5 Parrillo JE. Management of septic shock: present and future. Ann Intern Med 1991; 115: 491-93.
6. 6 Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278: 234-40.
7. 7 Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273: 117-23.
8. 8 Bone RC, Fisher CJ Jr, Clemmer TP, et al. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17: 389-93.
9. 9 Abraham E, Wunderink R, Silverman H, et al. Monoclonal antibody to human rumor necrosis factor alpha (TNFα MAb): efficacy and safety in patients with the sepsis syndrome. JAMA 1995; 273: 934-41.
10. 10 Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 1997; 277: 1531-34.
11. 11 Sherman ML, Spriggs DR, Arthur KA, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988; 6: 344-50.
12. 12 Van der Poll T, Buller HR, Ten Cate HT. Activation of coagulation after administration of TNF to normal subjects. N Engl J Med 1990; 322: 1622-27.
13. 13 Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-86.
14. 14 Cannon JG, Tompkins RG, Gelfand JA, et al. Circulating IL-1 and TNF in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79-84.
15. 15 Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-64.
16. 16 Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/TNF reduce interleukin-1 and interleukin-6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627-33.
17. 17 Opal SM, Cross AS, Kelly NM, et al. Efficacy of a monoclonal antibody directed against TNF in protecting neutropenic rats from lethal infection with P. aeruginosa. J Infect Dis 1990; 161: 1148-52.
18. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF). Circ Shock 1990; 30: 279-92.
19. 19 Hinshaw LB, Emerson TE Jr, Taylor FB Jr, et al. Lethal S. aureus shock in primates: prevention of death with anti-TNF antibody. J Trauma 1992; 33: 568-73.
20. 20 Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor α in patients with sepsis. Crit Care Med 1996; 24: 1431-40.
21. 21 Galloway CJ, Madanat MS, Mitra G. Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity. J Immunol Methods 1991; 140: 37-43.
22. 22 Pauli U, Bertoni G, Duerr M, Peterhans E. A bioassay for the detection of tumor necrosis factor from eight different species: evaluation of neutralization rates of a monoclonal antibody against human TNFα. J Immunol Methods 1994; 171: 263-65.
23. 23 Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-28.
24. 24 Tran DD, Groenveld ABJ, Meulen JVD, Nauta JJP, Strack van Schijndel RJM, Thijs LG. Age, chronic disease, sepsis, organ system failure and mortality in a medical intensive care unit. Crit Care 1990; 18: 474-79.
25. 25 Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-12.